{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:49:25Z","timestamp":1793922565051,"version":"4.8.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cpcardiol.2022.101439","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T21:32:15Z","timestamp":1664832735000},"page":"101439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring"],"prefix":"10.1016","volume":"48","author":[{"given":"Muhammad","family":"Umer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif F.","family":"Nagueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh K.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101439_bib0001","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0002","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0003","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0004","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.jacc.2011.10.825","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0005","series-title":"GeneReviews\u00ae","article-title":"Fabry Disease","author":"Mehta","year":"1993"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0007","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0008","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0011","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0012","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0013","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0014","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson-Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rce.2017.06.007","article-title":"The pathophysiology of Fabry disease","volume":"218","author":"Olivera-Gonz\u00e1lez","year":"2018","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0016","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0017","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0018","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0019","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0023","article-title":"Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation","volume":"22","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12968-015-0114-4","article-title":"A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease","volume":"17","author":"Kozor","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000803","article-title":"Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease","volume":"5","author":"Liu","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0028","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/echo.12079","article-title":"Two- and three-dimensional speckle tracking echocardiography: clinical applications and future directions","volume":"30","author":"Biswas","year":"2013","journal-title":"Echocardiography"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacc.2011.03.020","article-title":"Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease","volume":"58","author":"Calcagnino","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0031","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ehf2.13101","article-title":"Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy","volume":"8","author":"Graziani","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0032","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0033","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0034","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0035","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kr\u00e4mer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0036","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0037","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/clc.23019","article-title":"Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study","volume":"41","author":"Di","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0038","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.108.769729","article-title":"Angina in fabry disease reflects coronary small vessel disease","volume":"1","author":"Chimenti","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0039","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.008872","article-title":"Quantitative myocardial perfusion in Fabry Disease","volume":"12","author":"Knott","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0041","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry Disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0042","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","article-title":"Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies","volume":"54","author":"Desnick","year":"1976","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0043","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0044","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: A United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0046","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2011.09.052","article-title":"Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease","volume":"109","author":"Namdar","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0047","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/hrt.2010.211789","article-title":"Electrocardiographic changes in early recognition of Fabry disease","volume":"97","author":"Namdar","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0048","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.amjcard.2009.10.056","article-title":"PQ interval in patients with Fabry disease","volume":"105","author":"Namdar","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0049","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0050","doi-asserted-by":"crossref","first-page":"E8080","DOI":"10.3390\/ijms21218080","article-title":"Biomarkers in Anderson-Fabry disease","volume":"21","author":"Simonetta","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated Inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0052","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.hco.0000131534.25034.43","article-title":"Tissue doppler imaging in Fabry disease","volume":"19","author":"Pieroni","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0053","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0054","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehm454","article-title":"A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium","volume":"28","author":"Weidemann","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12574-020-00508-3","article-title":"Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain","volume":"19","author":"Tanaka","year":"2021","journal-title":"J Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0056","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0057","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0058","first-page":"1507","article-title":"Myocardial dimensions in children with hypertrophic cardiomyopathy: a comparison between echocardiography and cardiac magnetic resonance imaging","volume":"32","author":"Windram","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0059","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.echo.2015.12.011","article-title":"New reference centiles for left ventricular mass relative to lean body mass in children","volume":"29","author":"Foster","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/HCO.0000000000000346","article-title":"The continuing challenge of evaluating diastolic function by echocardiography in children: developing concepts and newer modalities","volume":"32","author":"Mawad","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0061","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0062","article-title":"Left ventricular mass and wall thickness measurements using echocardiography and cardiac MRI in patients with fabry disease: clinical significance of discrepant findings","volume":"2","author":"O'Brien","year":"2020","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0063","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1055\/s-0031-1281744","article-title":"Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy","volume":"183","author":"Wuest","year":"2011","journal-title":"Rofo"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0064","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","article-title":"Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease","volume":"18","author":"Deva","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0066","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0067","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"T\u2081 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex","volume":"6","author":"Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0068","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12968-014-0099-4","article-title":"Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance","volume":"16","author":"Pica","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0069","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157565","article-title":"reduced right ventricular native myocardial T1 in Anderson-Fabry disease: comparison to pulmonary hypertension and healthy controls","volume":"11","author":"Pagano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0071","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3348\/kjr.2017.18.1.113","article-title":"Myocardial T1 and T2 mapping: techniques and clinical applications","volume":"18","author":"Kim","year":"2017","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0072","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","article-title":"Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy","volume":"68","author":"Nordin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101439_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0074","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12968-019-0557-0","article-title":"Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy","volume":"21","author":"Mathur","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12968-022-00873-1","article-title":"SCMR expert consensus statement for cardiovascular magnetic resonance of acquired and non-structural pediatric heart disease","volume":"24","author":"Dorfman","year":"2022","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0076","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pcad.2012.01.003","article-title":"Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy","volume":"54","author":"Pelliccia","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0077","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/ehjci\/jez039","article-title":"Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group","volume":"20","author":"Imbriaco","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0078","article-title":"Early cardiac involvement affects left ventricular longitudinal function in females carrying \u03b1-Galactosidase a mutation: role of hybrid positron emission tomography and magnetic resonance imaging and speckle-tracking echocardiography","volume":"11","author":"Spinelli","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0079","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13244-021-01067-6","article-title":"Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study","volume":"12","author":"Nappi","year":"2021","journal-title":"Insights Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.echo.2010.05.020","article-title":"The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology","volume":"23","author":"Weidemann","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0081","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","article-title":"Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0082","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1148\/radiol.2019190651","article-title":"MRI T1 mapping in hypertrophic cardiomyopathy: evaluation in patients without late gadolinium enhancement and hemodynamic obstruction","volume":"294","author":"Xu","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0083","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/heartjnl-2016-309900","article-title":"High T2-weighted signal intensity is associated with elevated troponin T in hypertrophic cardiomyopathy","volume":"103","author":"Gommans","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0084","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jash.2015.11.006","article-title":"The septal bulge\u2013an early echocardiographic sign in hypertensive heart disease","volume":"10","author":"Gaudron","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0085","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.echo.2008.10.006","article-title":"Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: an ultrasonic two-dimensional speckle tracking study","volume":"21","author":"Kosmala","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0086","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1532-429X-14-50","article-title":"Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance","volume":"14","author":"Dweck","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0087","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1067\/j.cpradiol.2019.09.005","article-title":"Left ventricular hypertrophy: evaluation with cardiac MRI","volume":"49","author":"Grajewski","year":"2020","journal-title":"Curr Probl Diagn Radiol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101439_bib0088","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jcmg.2017.09.005","article-title":"Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0089","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacc.2019.11.032","article-title":"Extracellular myocardial volume in patients with aortic stenosis","volume":"75","author":"Everett","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0090","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/eurheartj\/ehr084","article-title":"Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis","volume":"32","author":"Ng","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0091","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0092","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0093","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0094","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0096","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0097","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0098","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0099","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","article-title":"MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease","volume":"160","author":"Koeppe","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0101","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0102","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0103","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ejechocard\/jer109","article-title":"Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease","volume":"12","author":"Zamorano","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0104","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","article-title":"Impaired left atrial function in fabry disease: a longitudinal speckle-tracking echocardiography study","volume":"30","author":"Pichette","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140627","article-title":"Left ventricular geometry and blood pressure as predictors of adverse progression of fabry cardiomyopathy","volume":"10","author":"Kr\u00e4mer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0106","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101439_bib0107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062200336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062200336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:03:47Z","timestamp":1758938627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062200336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S014628062200336X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101439","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101439"}}